Project Title
A multi-center phase I study of Codrituzumab (GC33, RG7686, RO5137382) in pediatric patients with relapsed or refractory GPC3 expressing solid tumors
Layman’s summary
CKc-funded Young Investigator Dr. Ortiz is launching his first clinical trial using an investigational immunotherapy drug currently in development for adult liver cancers. He is employing this medication for the first time in children with relapsed or refractory solid tumors that express a particular tumor-growing protein.
Michael Ortiz
This Project By The Numbers
